Medlab conducts clinical trials and partners with leading universities and hospitals. The research investigations test our novel therapies to evaluate the health outcomes that we strive to achieve.


Cancer and non-cancer related pain

An observational study investigating and auditing the safety, tolerability and further efficacy characteristics of a pharmaceutical grade cannabis medicine (NanaBis™) prescribed to eligible patients for the management of cancer related or non-cancer related pain in general and specialty medical practices.

 

The purpose of the study is to investigate the safety, tolerability and effectiveness of pharmaceutical-grade submicron particle cannabis (NanoCelle® 1:1 THC 8.93mg/ml and CBD 8.93mg/ml) in an oro-buccal spray, for the management of Cancer and Non-cancer related pain in general and specialty medical practices.
 

Who is it for?

Recruiting - You may be eligible for this study if you are an adult who has been prescribed NanaBis™ for either cancer-related or non-cancer related pain. 

More information

Bone Pain From Metastatic Cancer

NanaBis™ an Oro-Buccal Administered delta9-Tetrahydrocannabinol (d9-THC) and Cannabidiol (CBD) Medicine For The Management of Chronic Pain From Metastatic Bone Cancer

 

NanaBis™ ACTRN12621001302842

The purpose of this study is to determine whether a nanoparticle cannabis-based medicine (NanaBis™) containing 2.5 mg d9-THC and 2.5 mg CBD in a sub-micron (NanoCelle®) spray applied to the oro-buccal membrame, is effective in reducing metastatic bone pain in patients with cancer. The dose administered will be 2-3.5 doses (2 sprays to 7 sprays) per 4 hours unless asleep.

Who is it for?

Not yet recruiting - You may be eligible for this study if you are aged between 18-75 years old, have been diagnosed with any cancer that has metastasised to bone, and are experiencing bone pain.

More information

Depression

Combination of probiotics (each capsule contains 50 billion colony-forming units (CFU) of live organisms (Lactobacillus acidophilus +Lactobacillus casei +Lactobacillus rhamnosus JB-1)and magnesium orotate

 

NRGBiotic ACTRN12614000544673

This was a novel study investigated the benefits of NAC treatment in unipolar depression. Based on previous literature that reported deficits of this antioxidant in the brains of people with schizophrenia and bipolar disorder, the study postulated the deficits in unipolar depression patients. This trial involved adjunctive treatment where patients had received either NAC or placebo on top of their usual medication for a duration of 8 weeks.

Who is it for?

Completed - patients were eligible for this study if they were aged 18+, and met the criteria for major depressive disorder.


Chemotherapy-induced intestinal mucositis

The safety and tolerability of a multi-species probiotic formulation in chemotherapy-induced intestinal mucositis/diarrhoea: an exploratory end-point pilot study.

 

MultiBiotic ACTRN12618000927224

Phase 1 clinical trial evaluating whether probiotic supplementation prevents chemotherapy-induced diarrhoea and other intestinal adverse effects in cancer patients. The purpose of this study was to test the safety and tolerability of the MultiBiotic probiotic formulation before starting chemotherapy and until the end of treatment.

Who is it for?

Completed - participants were adults who had been diagnosed with cancer and had not yet commenced chemotherapy. Participants were aged between 18-75 years old.


NanoCelle™ Cannabidiol Pharmocokinetic Study

The buccal administration of a NanoCelle™ Cannabidiol formulation to healthy volunteers: a pharmacokinetic, safety and tolerability exploratory pilot study.

 

NanaBidial™ ACTRN12617001491358

This was a single blinded randomised placebo-controlled study. This study was performed in healthy subjects to determine the pharmacokinetic, safety and tolerability characteristics of a novel Cannabidiol formulation in the form of an oro-buccal spray. The drug contains 6 mg CBD and <0.3 mg other cannabinoids (including THC)/0.3 mL in 2 actuations of the pump (equals 1 dose).

Who is it for?

Completed - participants were healthy and 18 years or above.